---

---

entities : Astellas pharma inc    symbols : Pfe   

save search

---

Orphan Drugs Market Projection: BCC Research Anticipates a Staggering $415.2 Billion Valuation by 2028, Reflecting Soaring Global Demand
Published: 2024-02-09 (Crawled : 10:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -13.24% | O: -0.91% H: 3.88% C: 3.88%
AZNCF | News | $138.73 -4.19% 3.7K |

Health Technology

| 12.24% | O: -2.6% H: 2.26% C: 1.44%
NVSEF | News | $95.11 6.88% 490 |

Health Technology

| -7.06% | O: -2.46% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -11.56% | O: 4.66% H: 0.0% C: -3.92%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -4.53% | O: -0.04% H: 0.11% C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M |

Health Technology

| -2.47% | O: -0.37% H: 0.21% C: 0.05%
ABBV | News | $169.54 0.98% -0.91% 4.1M |

Health Technology

| -2.8% | O: 0.33% H: 0.0% C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| 2.1% | O: 1.11% H: 0.0% C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M |

Health Technology

| 11.54% | O: -1.28% H: 1.05% C: -0.72%
research global market

---

Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -17.75% | O: 4.34% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -17.98% | O: 0.0% H: 1.38% C: 0.26%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -2.59% | O: 0.56% H: 1.25% C: -0.33%
keytruda drug japan bladder cancer treatment application advanced

---

Astellas Announces Strategic Collaboration with Mass General Brigham
Published: 2024-01-30 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -17.75% | O: 4.34% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -17.98% | O: 0.0% H: 1.38% C: 0.26%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -2.59% | O: 0.56% H: 1.25% C: -0.33%
collaboration

---

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
Published: 2024-01-30 (Crawled : 12:30) - biospace.com/
GNMSF | News | $289.67 3.83% 5.3K |

Health Technology

| 5.23% | O: 2.14% H: 1.03% C: -0.89%
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -16.3% | O: 1.76% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -18.19% | O: -3.53% H: 3.49% C: 3.4%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -4.22% | O: 1.49% H: 1.72% C: -3.12%
GMAB | News | $28.54 -1.48% -1.51% 560K |

Health Technology

| 0.95% | O: 0.42% H: 0.04% C: -0.99%
ARVN | $33.96 -2.69% -2.77% 530K |

Health Technology

| -14.01% | O: -0.46% H: 0.79% C: 0.28%
financial results

---

European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -21.29% | O: -6.38% H: 0.88% C: 0.88%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -17.05% | O: 0.09% H: 0.17% C: -0.3%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -4.19% | O: 0.58% H: 1.01% C: -0.58%
keytruda bladder cancer treatment application advanced

---

EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
Published: 2023-12-17 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -17.39% | O: 0.0% H: 0.0% C: -0.7%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -16.46% | O: 0.79% H: 0.35% C: -0.26%
UVV | $51.87 2.33% 0.0% 500K |

Consumer Non-Durables

| -18.08% | O: 0.0% H: 0.05% C: -1.86%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -1.16% | O: 1.09% H: 1.41% C: 0.52%
children treatment ema

---

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Published: 2023-12-15 (Crawled : 22:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| Email alert Add to watchlist
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| Email alert Add to watchlist
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| Email alert Add to watchlist
padcev fda first approved bladder cancer treat advanced plus

---

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -19.29% | O: 3.87% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -21.96% | O: -3.37% H: 4.51% C: 4.51%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -13.62% | O: -4.92% H: 1.48% C: -0.21%
padcev fda license review bladder cancer treatment application grants

---

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Published: 2023-11-29 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -21.57% | O: 0.66% H: 0.0% C: -0.16%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -12.5% | O: 0.76% H: 0.66% C: 0.53%
women therapy hormone

---

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -18.1% | O: 0.04% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -17.98% | O: 1.38% H: 1.79% C: 1.79%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -11.59% | O: 0.5% H: 0.3% C: 0.0%
xtandi fda approved cancer treatment

---

Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research
Published: 2023-11-10 (Crawled : 15:00) - prnewswire.com
AZNCF | News | $138.73 -4.19% 3.7K |

Health Technology

| 10.59% | O: 0.1% H: 0.0% C: -2.14%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -19.44% | O: -3.48% H: 3.87% C: 3.61%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -11.32% | O: 0.24% H: 0.22% C: -0.91%
JNJ | News | $149.56 0.3% 0.0% 9.1M |

Health Technology

| -0.24% | O: -1.24% H: 0.0% C: 0.0%
BMY | $48.99 -0.31% 0.0% 9.1M |

Health Technology

| -2.82% | O: 0.4% H: 0.18% C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M |

Health Technology

| 22.82% | O: 0.44% H: 0.0% C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M |

Health Technology

| 10.55% | O: -1.33% H: 0.22% C: -0.11%
report research market

---

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
Published: 2023-10-15 (Crawled : 00:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -27.48% | O: -0.53% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -27.22% | O: -4.14% H: 2.4% C: 1.92%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -18.03% | O: 2.24% H: 3.32% C: 1.34%
congress

---

Global Vulvovaginal Candidiasis Treatment Market Research Report 2023-2028 - Demand for Cost-effective Vulvovaginal Candidiasis Treatment Soars with Growing Geriatric Population
Published: 2023-10-04 (Crawled : 23:00) - prnewswire.com
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -29.76% | O: 0.59% H: 0.29% C: 0.22%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -20.98% | O: 0.42% H: 0.99% C: 0.06%
SCYX | $1.53 6.25% 5.88% 150K |

Health Technology

| -30.18% | O: 0.45% H: 4.04% C: 0.45%
CDTX | News | $0.5141 0.04% 0.04% 1.9M |

Health Technology

| -45.16% | O: 0.39% H: 10.33% C: 3.9%
report treatment candidiasis research global growing market

---

RNA Therapeutics Market worth $18.0 billion | MarketsandMarkets
Published: 2023-09-15 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -13.01% | O: 1.53% H: 0.0% C: 0.0%
NVSEF | News | $95.11 6.88% 490 |

Health Technology

| 13.27% | O: 0.79% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -36.69% | O: 3.0% H: 0.0% C: -3.43%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -22.93% | O: -0.26% H: 1.04% C: 0.03%
NVS | News | $97.28 2.27% 0.31% 3.7M |

Health Technology

| -2.92% | O: 1.51% H: 0.26% C: -0.72%
SRPT | $117.065 0.09% 0.09% 440K |

Health Technology

| -2.17% | O: -0.27% H: 0.54% C: -0.84%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -13.73% | O: 0.82% H: 0.0% C: 0.0%
MRNA | News S | $107.87 3.26% 3.16% 2.4M |

Health Technology

| -4.36% | O: 0.16% H: 2.0% C: 1.42%
IONS | $41.85 1.9% 1.86% 630K |

Health Technology

| -4.12% | O: -0.57% H: 0.35% C: -1.11%
BNTX | News | $88.53 0.59% 0.59% 360K |

Health Technology

| -22.25% | O: 0.17% H: 0.48% C: -0.82%
ARWR | $23.775 -0.61% -0.61% 830K |

Health Technology

| -22.13% | O: 0.16% H: 0.46% C: -5.46%
ALNY | $146.06 0.19% 0.18% 540K |

Health Technology

| -24.34% | O: -0.74% H: 2.42% C: -3.47%
therapeutics market

---

European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-09-12 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -36.22% | O: -0.03% H: 1.04% C: -0.37%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -22.93% | O: 0.18% H: 1.2% C: -0.38%
xtandi cancer treatment

---

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -37.77% | O: 0.59% H: 0.46% C: 0.46%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -28.56% | O: 0.68% H: 0.11% C: -1.16%
xtandi fda review cancer grants

---

North America Kidney Transplant Research Report 2023
Published: 2023-08-08 (Crawled : 22:00) - prnewswire.com
NVSEF | News | $95.11 6.88% 490 |

Health Technology

| 15.65% | O: 1.11% H: 0.53% C: 0.53%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -36.78% | O: 3.93% H: 0.0% C: -3.08%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -26.15% | O: -0.11% H: 1.29% C: 0.67%
NVS | News | $97.28 2.27% 0.31% 3.7M |

Health Technology

| -4.07% | O: -0.07% H: 0.73% C: 0.36%
MDT | $81.29 0.89% 0.0% 5.2M |

Health Technology

| -3.15% | O: -1.98% H: 1.7% C: 0.81%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -9.87% | O: 0.81% H: 0.0% C: 0.0%
america report kidney research

---

Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| -43.95% | O: -1.8% H: 0.0% C: 0.0%
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -43.46% | O: -1.4% H: 0.3% C: 0.01%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -30.43% | O: 0.56% H: 1.05% C: -1.16%
asco cancer pipeline meeting

---

XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide
Published: 2023-04-29 (Crawled : 16:20) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| Email alert Add to watchlist
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| Email alert Add to watchlist
ALPMF | News | $9.75 43.47% 200 |

Health Technology

| Email alert Add to watchlist
xtandi cancer risk plus

---

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Published: 2023-03-16 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.53 -1.11% 690K |

Manufacturing

| -31.58% | O: -0.18% H: 0.25% C: 0.25%
PFE | News 4 | $26.32 0.23% 0.0% 24M |

Health Technology

| -34.8% | O: 0.63% H: 0.41% C: -1.29%
xtandi cancer plus study

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---